Aldeyra’s reproxalap meets primary goal in Phase II dry eye disease trial
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Aldeyra’s reproxalap meets primary goal in Phase II dry eye disease trial

03 Nov 2021 (Last Updated November 3rd, 2021 14:23)

No safety or tolerability issues linked to the treatment with reproxalap were noted in the trial.

Aldeyra Therapeutics has reported that its new experimental drug reproxalap met the primary goal of ocular redness in a Phase II clinical trial in individuals with dry eye disease, a common inflammatory ailment.

The double-masked, randomised, vehicle-controlled Phase II trial recruited 158 subjects, of which 80 were given a 0.25% ophthalmic solution of reproxalap while 78 subjects received vehicle ophthalmic solution.

Findings from the trial showed that ocular redness scores in the reproxalap arm were statistically less than those receiving a vehicle.

Following the first dose, Schirmer’s test results favoured reproxalap as against vehicle and neared statistical significance.

At all 18 time points of symptom evaluation in the dry eye chamber, subjects in the reproxalap group had reduced mean visual analogue scale ocular dryness and ocular discomfort scores versus those in vehicle arm.

The company noted that these differences were not statistically significant.

No safety or tolerability concerns were reported in the trial, which is in line with the clinical data of reproxalap in more than 1,300 subjects.

Mild and temporary instillation site discomfort that lasted for less than a minute was the most common side effect, which is similar to several prescribed topical ophthalmic treatments for anterior segment inflammation.

Aldeyra Therapeutics president and CEO Todd Brady said: “Complementing our rapid and durable symptom control evidenced in three 12-week clinical trials, we are excited to announce the achievement of statistical significance of an objective sign of dry eye disease in a well-controlled clinical trial.

“Ocular redness may be the only dry eye disease sign that is of importance to patients, and the reduction in redness observed in this trial following reproxalap treatment potentially represents a major advance for the chronic treatment of dry eye disease.”

Reproxalap is also currently being analysed in TRANQUILITY and TRANQUILITY-2 Phase III trials in dry eye disease patients.

Both the trials each intend to enrol 300 subjects, with ocular redness being the primary goal.